CHI3L1 and Creutzfeldt Jacob disease: These findings underscore CHI3L1’s potential as a biomarker for early diagnosis and monitoring of CJD progression, while also suggesting its relevance for exploring therapeutic interventions targeting neuroinflammation in prion disorders.